Pharmacy Benefit Managers Are Quietly Consolidating Specialty Drug Distribution

The Quiet Takeover of Specialty Drug Distribution

Pharmacy benefit managers – the companies that sit between insurers, employers, and pharmacies to negotiate drug pricing and coverage – have spent years expanding their influence across the healthcare supply chain. Now, they are moving aggressively into specialty drug distribution, a segment of the market that handles some of the most expensive and complex medications available: biologics, cancer treatments, immunosuppressants, and infusion therapies. The move is reshaping how these drugs reach patients, and not always in ways that benefit them.

Specialty drugs represent a small fraction of total prescriptions but account for a disproportionately large share of total drug spending in the United States. Because these medications often require temperature-controlled shipping, patient monitoring, and insurance prior authorization, they flow through a separate channel from standard retail pharmacy – typically through specialty pharmacies with specific accreditations and clinical support infrastructure. That infrastructure is now increasingly owned, operated, or exclusively contracted by the same PBMs that determine whether a drug is covered in the first place.

That vertical integration is the core concern.

How PBMs Captured the Specialty Channel

The three largest PBMs in the country – CVS Caremark, Express Scripts, and OptumRx – each operate their own specialty pharmacy arms. CVS Caremark runs Specialty Pharmacy through its Caremark division. Express Scripts, now part of Cigna, directs specialty volume through Accredo. OptumRx, owned by UnitedHealth Group, routes much of its specialty business through Optum Specialty Pharmacy. Each of these entities is accredited, licensed, and positioned to capture the high-margin end of drug distribution – then steered toward by the same parent company that manages the drug benefit for millions of insured Americans.

The mechanism is straightforward: a PBM controls which drugs are on a plan’s formulary, sets the reimbursement rates paid to pharmacies, and determines which pharmacies are included in a plan’s network. When the PBM also owns a specialty pharmacy, there is a clear financial incentive to route patients toward that pharmacy – even when independent or hospital-based specialty pharmacies might provide equivalent or better service. Some insurance plan designs restrict specialty drug fills exclusively to the PBM-owned pharmacy, leaving patients with no in-network alternative for medications they may need monthly or indefinitely.

Independent specialty pharmacies have raised concerns about this arrangement for years, arguing that PBMs use their dual role – as both benefit managers and pharmacy operators – to disadvantage competitors through below-cost reimbursements, narrow network exclusions, and clinical criteria designed to keep patients on more profitable formulary alternatives. The Federal Trade Commission opened a study into PBM practices, and its interim report released in 2024 described a concentrated market in which the largest PBMs increasingly favor their own affiliated pharmacies. The report stopped short of recommending specific remedies but documented the structural conflict in detail.

What This Means for Patients and Employers

For patients on specialty medications – often people managing chronic or serious illnesses – the consolidation translates into fewer choices and less negotiating power. A patient whose plan routes all specialty drugs through one PBM-owned pharmacy cannot comparison shop for better clinical support, faster prior authorization turnaround, or more convenient delivery options. If the designated pharmacy has service problems, there is frequently no practical alternative within network. This is especially problematic for patients in rural or underserved areas where access to independent specialty pharmacy support is already limited. The closure of independent retail pharmacies across rural counties has only deepened that dependency on PBM-affiliated distribution networks.

Employers who self-fund their health benefits – which covers a large share of privately insured Americans – often have limited visibility into how their PBM is routing specialty claims or what spread pricing is occurring between what the PBM charges the plan and what it actually pays the pharmacy. Specialty drugs carry very high list prices, and the margin between acquisition cost and what a PBM-owned pharmacy bills the employer can be significant. Because these arrangements are typically embedded in multi-year PBM contracts with complex fee structures, most employers lack the data infrastructure to audit them without third-party consultants.

Some large employers and union benefit funds have started pushing back, demanding pass-through pricing models where the plan pays the actual net cost of the drug rather than a marked-up price set by the PBM. A growing number of sophisticated plan sponsors are also carving out specialty drug management to independent firms, or contracting directly with manufacturer patient assistance programs to reduce PBM leverage. These strategies work when employers have negotiating scale and internal benefits expertise – conditions that most mid-sized or small employers simply do not have.

Regulatory Scrutiny and What Comes Next

Congress has held multiple hearings on PBM consolidation, and legislation requiring greater transparency in specialty drug pricing has moved through committee in recent sessions without becoming law. The political challenge is that PBMs argue, with some basis, that their scale and negotiating leverage produce lower drug costs for plan sponsors – even when the routing practices favor their own pharmacies. Disentangling where PBM integration genuinely produces savings versus where it extracts margin at the patient or employer’s expense requires detailed claims-level data that most regulators do not have access to and that PBMs treat as proprietary.

State-level action has moved faster. Several states have passed legislation requiring PBMs to obtain separate licensure, prohibiting certain spread pricing practices in Medicaid contracts, and mandating that any pharmacy meeting clinical accreditation standards be included in specialty drug networks. Enforcement has been uneven, and PBMs have challenged some of these laws on ERISA preemption grounds, arguing that federal employee benefit law prevents states from regulating PBM conduct within self-funded employer plans. Those legal challenges are ongoing, and the outcome will define how much authority states actually have to intervene.

The FTC’s full report on PBM practices – still pending as of this writing – is expected to include more direct policy recommendations. Whether those recommendations lead to structural remedies, mandatory divestiture of pharmacy assets, or binding transparency rules remains an open question. What is not in question is the direction of the market: PBMs are not retreating from specialty distribution, they are building deeper infrastructure around it, and every year that consolidation continues without regulatory constraint makes unwinding it more difficult and more expensive.